News
04-27-2020, 12:12 PM
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
More... (https://www.news-medical.net/news/20200427/Talazoparib-did-not-show-overall-survival-benefit-in-patients-with-advanced-BRCA-mutated-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20200427/Talazoparib-did-not-show-overall-survival-benefit-in-patients-with-advanced-BRCA-mutated-breast-cancer.aspx)